Assessment of cryopreserved human hepatocytes as a model system to investigate sulfation and glucuronidation and to evaluate inhibitors of drug conjugation

Xenobiotica

Volumn 39, Issue 5, 2009, Pages 374-381

  Riches, Z ^a   Bloomer, J ^b   Patel, A ^b   Nolan, A ^b   Coughtrie, M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cryopreservation; Glucuronidation; Hepatocytes; Inhibition; Paracetamol; Sulfation

Indexed keywords

CISAPRIDE; NIZATIDINE; PARACETAMOL; PHENYTOIN; PROBENECID; RANITIDINE; SULFINPYRAZONE; TRANILAST; VALPROIC ACID; XENOBIOTIC AGENT;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SULFATION; ENZYME KINETICS; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL;

ACETAMINOPHEN; CELL SURVIVAL; CELLS, CULTURED; CRYOPRESERVATION; DRUG INTERACTIONS; GLUCURONIDES; HEPATOCYTES; HUMANS; KINETICS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SULFATES;

EID: 70350680427     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250902763440     Document Type: Article

References (34)

1. Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. (2008). Interindividual variability in acetaminophen sulfation by human fetal liver: Implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defect Res A: Clin Mol Teratol. 82:155-165
2. Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Disposit 35:293-301.
3. Clements JA, Critchley JAJH, Prescott LF. (1984). The role of sulfate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br J Clin Pharmacol 18:481-485
4. Coughtrie MWH, Gilissen RAHJ, Shek B, Strange RC, Fryer AA, Jones PW, Bamber DE. (1999). Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 337:45-49
5. Court M, Duan SX, Von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDPglucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
6. Critchley JAJH, Critchley LAH, Anderson PJ, Tomlinson B. (2005). Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. J Clin Pharm Ther 30:179-184
7. Critchley JAJH, Nimmo GR, Gregson CA, Woolhouse NM, Prescott LF. (1986). Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol 22:649-657
8. Fayz S, Cherry WF, Dawson JR, Mulder GJ, Pang KS. (1984). Inhibition of acetaminophen sulfation by 2,6-dichloro-4-nitrophenol in the perfused rat liver preparation. Lack of a compensatory increase of glucuronidation. Drug Metab Disposit 12:323-329
9. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, Yokoi T. (2008). Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab Disposit 36:361-367
10. Hirata-Koizumi M, Saito M, Miyake S, Hasegawa R. (2007). Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA. J Clin Pharm Ther 32:177-185
11. Itoh H, Nagano T, Takeyama M. (2001). Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. J Pharm Pharmacol 53:1041-1045
12. Itoh H, Nagano T, Takeyama M. (2002). Effect of nizatidine on paracetamol and its metabolites in human plasma. J Pharm Pharmacol 54:869-873
13. Kamali F. (1993). The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur J Clin Pharmacol 45:551-553
14. Katoh M, Matsui T, Yokoi T. (2007). Glucuronidation of antiallergic drug, tranilast: Identification of human UDPglucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Disposit 35:583-589
15. Kerdpin O, Elliot DJ, Mackenzie PI, Miners JO. (2006). Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDPglucuronosyltransferase 1A9. Drug Metab Disposit 34:1950-1953
16. Khetani SR, Bhatia SN. (2008). Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126
17. Kiang TK, Ensom MH, Chang TK. (2005). UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
18. Kostrubsky SE, Strom SC, Ellis E, Nelson SD, Mutlib AE. (2007). Transport, metabolism, and hepatotoxicity of flutamide, drug- drug interaction with acetaminophen involving phase I and phase II metabolites. Chem Res Toxicol 20:1503-1512
19. Li AP. (2007). Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chemico-Biol Interact 168:16-29.
20. Liu L, Klaassen CD. (1996). Different mechanisms of saturation of acetaminophen sulfate conjugation in mice and rats. Toxicol Appl Pharmacol 139:128-134
21. Marchetti F, De SC, Vietri M, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. (2001). Differential inhibition of human liver and duodenum sulphotransferase activities by quercetin, a flavonoid present in vegetables, fruit and wine. Xenobiotica 31:841-847
22. Miners JO, Lillywhite KJ, Yoovathaworn K, Pongmarutai M, Birkett DJ. (1990). Characterization of paracetamol UDPglucuronosyltransferase activity in human liver microsomes. Biochem Pharmacol 40:595-600.
23. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S. (2006). Kinetics of acetaminophen glucuronidation by UDP- glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem Res Toxicol 19:701-709
24. Nagar S, Walther S, Blanchard RL. (2006). Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol 69:2084-2092
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
26. Oddy EA, Manchee GR, Coughtrie MWH. (1997). Assessment of rat liver slices as a suitable model system for studying the simultaneous sulphation and glucuronidation of phenolic xenobiotics. Xenobiotica 27:369-377
27. Patel M, Tang BK, Kalow W. (1992). Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics 2:38-45.
28. Reiter C, Weinshilboum R. (1982). Platelet phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen. Clin Pharmacol Ther 32:612-621
29. Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie MWH. (2001). Sulfation of thyroid hormone and dopamine during human development - ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung and brain. J Clin Endocrinol Metab 86:2734-2742
30. Rogers SM, Back DJ, Stevenson PJ, Grimmer SFM, Orme L-E. (1987). Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol. Br J Clin Pharmacol 23:721-725
31. Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD. (2004). Sulfotransferase 1E1 is a low Km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Disposit 32:1299-1303
32. Singh SS. (2006). Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 7:165-182
33. Soars MG, McGinnity DF, Grime K, Riley RJ. (2007). The pivotal role of hepatocytes in drug discovery. Chemico-Biol Interact 168:2-15.
34. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) 'probes' for human UDPglucuronosyltransferases. Drug Metab Disposit 34:449-456